Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability
A compound called ERX-41 targets a previously unrecognized vulnerability in difficult-to-treat types of cancer including triple-negative breast cancer. The compound will be studied as a drug for clinical translation.
Read Original Article: Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability »
